Dr. Kenneth Tew is an international leader in cancer drug discovery and development. His earlier research was pivotal in the design of treatments for hormone refractory prostate cancer. More recently his research has been instrumental in the late-stage clinical testing of three novel drugs; one shows promise in treating ovarian and lung cancer, and another has potential as a modifier of bone marrow mediated immune function.
Dr. Tew is also working to understand how cancer cells develop resistance to different drugs. As part of that work, discoveries have suggested links between cancer and Alzheimer’s. The creation of a new knockout mouse (genetically engineered with one or more inoperable genes) may provide a useful model for studying these diseases.
Highly respected by his colleagues, Dr. Tew was elected Chair of Drug Discovery & Regulatory Affairs for the American Society for Pharmacology and Experimental Therapeutics (2011-2013) and Chair for the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (2012-2015).